GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug BioSpace
Regulatory Approvals
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science – Dana
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science Dana-Farber Cancer Institute
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC Oncodaily
FDA Approves Zidesamtinib (Jideytro) for ROS1-Positive Non-Small Cell Lung Cancer
FDA Approves Zidesamtinib (Jideytro) for ROS1-Positive Non-Small Cell Lung Cancer Oncology News Central
With FDA approval, Celcuity sees big future for its new breast cancer drug
With FDA approval, Celcuity sees big future for its new breast cancer drug Star Tribune